mapping the effectiveness and risks of glp-1 receptor agonists - Nature Medicine Author Correction: Mapping the effectiveness

Discovery of gastric inhibitory polypeptide and its subsequent fate: personal reflections

Also this is extrapolated data C) As a sell side analyst we have only seen cos upgrade their forecast for FY27 D) Inventory - the bigger cos / bigger brands are still selling and no inventory is visible

Who Should Consider Oral GLP-1 Options Despite lower effectiveness, oral semaglutide makes sense for a specific subset of patients

Even mild but persistent symptoms can lead to treatment discontinuation, particularly in non-diabetic individuals using these agents primarily for weight management, who may have lower thresholds for tolerability than diabetic patients

Yes, they can cause side effects from skin irritation or issues with adhesives

The drivers behind these disparities are well-documented: structural racism, food insecurity, differential access to safe spaces for physical activity, and socioeconomic deprivation